These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25421091)

  • 1. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain.
    King B; Marshall N; Beard H; Hassiotis S; Trim PJ; Snel MF; Rozaklis T; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2015 Mar; 38(2):341-50. PubMed ID: 25421091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA.
    King B; Marshall NR; Hassiotis S; Trim PJ; Tucker J; Hattersley K; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2017 May; 40(3):443-453. PubMed ID: 27832416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
    King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
    Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.
    Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ
    Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement reduces neuropathology in MPS IIIA dogs.
    Crawley AC; Marshall N; Beard H; Hassiotis S; Walsh V; King B; Hucker N; Fuller M; Jolly RD; Hopwood JJ; Hemsley KM
    Neurobiol Dis; 2011 Aug; 43(2):422-34. PubMed ID: 21550404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.
    Mader KM; Beard H; King BM; Hopwood JJ
    Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.
    Hemsley KM; King B; Hopwood JJ
    Mol Genet Metab; 2007 Mar; 90(3):313-28. PubMed ID: 17166757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods.
    Marshall NR; Hassiotis S; King B; Rozaklis T; Trim PJ; Duplock SK; Winner LK; Beard H; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM
    Exp Neurol; 2015 Jan; 263():79-90. PubMed ID: 25246230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
    Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
    Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.
    King B; Setford ML; Hassiotis S; Trim PJ; Duplock S; Tucker JN; Hattersley K; Snel MF; Hopwood JJ; Hemsley KM
    Exp Neurol; 2016 Apr; 278():11-21. PubMed ID: 26626972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain Targeting in MPS-IIIA.
    Sorrentino NC; Fraldi A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():630-8. PubMed ID: 27491210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs.
    Yogalingam G; Pollard T; Gliddon B; Jolly RD; Hopwood JJ
    Genomics; 2002 Feb; 79(2):150-3. PubMed ID: 11829484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.
    Hemsley KM; Luck AJ; Crawley AC; Hassiotis S; Beard H; King B; Rozek T; Rozaklis T; Fuller M; Hopwood JJ
    Eur J Neurosci; 2009 Mar; 29(6):1197-214. PubMed ID: 19302155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
    Magat J; Jones S; Baridon B; Agrawal V; Wong H; Giaramita A; Mangini L; Handyside B; Vitelli C; Parker M; Yeung N; Zhou Y; Pungor E; Slabodkin I; Gorostiza O; Aguilera A; Lo MJ; Alcozie S; Christianson TM; Tiger PMN; Vincelette J; Fong S; Gil G; Hague C; Lawrence R; Wendt DJ; Lebowitz JH; Bunting S; Bullens S; Crawford BE; Roy SM; Woloszynek JC
    J Biol Chem; 2022 Dec; 298(12):102625. PubMed ID: 36306823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of cerebellar pathology in the canine model of mucopolysaccharidosis type IIIA (MPS IIIA).
    Hassiotis S; Jolly RD; Hemsley KM
    Mol Genet Metab; 2014 Dec; 113(4):283-93. PubMed ID: 25453402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA.
    King B; Savas P; Fuller M; Hopwood J; Hemsley K
    Mol Genet Metab; 2006 Feb; 87(2):107-12. PubMed ID: 16352454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continual Low-Dose Infusion of Sulfamidase Is Superior to Intermittent High-Dose Delivery in Ameliorating Neuropathology in the MPS IIIA Mouse Brain.
    Beard H; Hassiotis S; Luck AJ; Rozaklis T; Hopwood JJ; Hemsley KM
    JIMD Rep; 2016; 29():59-68. PubMed ID: 26620043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
    Wijburg FA; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Nestrasil I; Shapiro E; Jones SA; Alexanderian D
    Mol Genet Metab; 2021 Dec; 134(4):317-322. PubMed ID: 34600820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.